

# Feline hypertension: How and when to treat

Based on ACVIM guidelines, this easy-to-follow guide helps you identify cats at risk of hypertension, monitor them effectively and decide when to start treatment.<sup>1</sup>

Cats are at risk of hypertension if they:




Have evidence of target organ damage (TOD) (see overleaf)

OR




Have a disease associated with hypertension, e.g. chronic kidney disease (CKD) or hyperthyroidism

OR



Are aged 9 years or older

For cats at risk




The initial recommended dose of Semintra® 10 mg/ml oral solution for cats is 0.2 ml/kg body weight.<sup>2</sup>  
The target SBP range is between 120 and 140 mmHg.<sup>2</sup>  
After 4 weeks, the dose of Semintra® may be reduced in cats with SBP of <140 mmHg (in 0.5 mg/kg increments), at the vet's discretion. If SBP increases over the course of the disease, the daily dose may be increased again up to 2 mg/kg.<sup>2</sup>  
In cats with hypertension associated with CKD, the recommended effective dose is not lower than 1 mg/kg.<sup>2</sup>  
Adapted from ACVIM guidelines, Acierno, et al. 2018.<sup>1</sup>




**Semintra**  
THE SOLUTION

# Evidence of target organ damage

In cats, the target systolic blood pressure (SBP) is 120–140 mmHg.<sup>2</sup> When SBP  $\geq$ 160 mmHg there is an increased risk of damage to the eyes, brain, kidneys and heart, collectively known as the target organs.<sup>1,3</sup>



## Semintra<sup>®</sup>, the only liquid solution for feline hypertension



Find out more about Semintra<sup>®</sup>.  
Learn and earn free CPD points at  
[www.boehringer-academy.co.uk](http://www.boehringer-academy.co.uk)

Semintra<sup>®</sup> 10 mg/ml oral solution for cats contains telmisartan. Semintra<sup>®</sup> is indicated for treatment of systemic hypertension in cats. UK: POM-VIE: POM. For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet.

Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: [vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com). Semintra<sup>®</sup> is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. © 2020 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: May 2020. UI-FEL-0036-2020. Use Medicines Responsibly.

#### References

1. Acierno MJ, et al. *J Vet Intern Med.* 2018;1-20.

2. Semintra<sup>®</sup> Summary of Product Characteristics. 2018.

3. Taylor SS, et al. *J Feline Med and Surgery.* 2017;19:288-303.

SDMA: symmetric dimethylarginine, a renal biomarker specific to kidney function



**Semintra**  
THE SOLUTION